Generated $58.6 million in revenue from resilient royalties portfolio Achieved IST U.S. net product sales of $34.2 million for the first quarter, representing 29% year-over-year...
Barchart Research What to Expect from INVA Earnings INVA Generated May 5, 2026 Current Price $22.65 EPS Estimate $$0.43 Consensus Rating Moderate Buy Average Move 3.03% Innoviva's Royalty Foundation Meets...
Three low P/E small-cap stocks offer distinct catalysts and upside potential as investors look ahead to a broader market rally
Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year IST achieved U.S. net product sales of $33.9...
Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva...
Significant updates from the FDA toward the end of 2025 have rallied investor interest in Axsome and Innoviva, two high-potential biotech names for 2026.
FDA approval was based on results from the largest Phase 3 clinical trial ever conducted for a new treatment against Neisseria gonorrhoeae infection in regions with a high prevalence...
Phase 3 findings show oral zoliflodacin to be non-inferior to the combination of ceftriaxone and azithromycin for the treatment of uncomplicated urogenital gonorrhea. Positive...